News & Updates
Filter by Specialty:
Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.
Pyrotinib + capecitabine extends OS in metastatic breast cancer
10 Jan 2022
5α-reductase inhibitors help reduce SARS-CoV-2 infection risk in men
Use of 5α-reductase inhibitors (5ARIs) appears to lower the risk of community-acquired infection with SARS-CoV-2 in men without prostate cancer, according to a study, noting that treatment with this drug class can help ease the burden of COVID-19.
5α-reductase inhibitors help reduce SARS-CoV-2 infection risk in men
10 Jan 2022
Lower rates of digestive cancer treatment in older patients due to pandemic lockdowns
The coronavirus disease 2019 (COVID-19) pandemic has led to a sharp decline in treatment for older patients with newly diagnosed cancers of the digestive system, a recent study has found.
Lower rates of digestive cancer treatment in older patients due to pandemic lockdowns
10 Jan 2022
Disease-modifying agents for multiple sclerosis do not elevate cancer risk
Several disease-modifying therapies (DMTs) for multiple sclerosis (MS) do not pose an increased risk of cancer, a study has shown.
Disease-modifying agents for multiple sclerosis do not elevate cancer risk
09 Jan 2022
Opioid use lowers LOS, deaths in nonmetastatic CRC patients
Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.
